Some results expected by end 2000. Increasing body's own production of neurotrophic factors, if possible, would be an advantage over delivering these factors as drugs. A major problem with giving these large molecules is that they don't readily enter the central nervous system. On market since 1996. Rilutek showed modest prolongation of life in ALS patients in very large U.S. and European trials.
Liver toxicity is a frequent side effect.
Regular blood tests to check for this are needed. Usually covered by insurance, since approved for ALS treatment. RPR runs patient assistance program through Athena Home Pharmacy to help find financial aid. Parke-Davis Glutamate Inhibitor Probably partially blocks glutamate synthesis. On market for epilepsy.